FuturedMe Inc.

Program name

Deep-Tech Startups Support Program

Research theme

Construction of drug development platform of disease-specific degradation by CANDDY

Business Plan

In the era of precision medicine, genomic medicine needs to solve the problem (pain) that even if the causative molecule (target) of a disease is identified, there is no therapeutic drug for the target. To this end, we will raise the barrier to entry for CANDDY, the next-generation degradative drug discovery technology, and build a disease-specific degradative drug development platform that will establish a differentiated prototype, expand the market, and reduce side effects.

Research Outline

In this research and development, we will construct the "Immune CANDDY Platform" as a degradative drug development technology that does not act on normal cells but can target degradation only in cancer cells due to immunoproteasome selectivity.

〔1〕Shows the difference in the degradation index (DC50) between normal cells and diseased cells.

〔2〕Shows the degradation of naturally denatured proteins.

〔3〕Showing the POC of the initial prototype of the CANDDY molecule.

International collaborative technology demonstration

• Download this page（186KB）